Introduction
Investigators studying the nervous system form two groups: those striving to understand neuronal differentiation, connectivity, and function (basic scientists), and those studying neurological disorders, disease pathogenesis, and therapeutics (clinicians and clinical researchers). With the identification of the molecular bases of several neurological disorders, the two principal challenges are the proper allocation of investments in basic and clinical research and acceleration of the discovery and development of therapies. Bearing these two challenges in mind, we take a historical perspective in this Essay and analyze three "success stories" in the field of neurological disease research.
These examples share two key ingredients. First, basic research contributions advance the understanding of disease mechanisms and provide a rich source of pathways for therapeutic targeting. This demonstrates that investment in basic research provides substantial clinical returns. Second, the astute observations of clinicians are essential for placing basic research findings into the appropriate clinical framework. These examples clearly reveal that basic research provides the seeds for clinical discoveries and that only through the union of basic research and clinical medicine can we hope to overcome the challenges inherent in diagnosing and curing neurological disease.
Marrying Basic Research to Clinical Intervention: Parkinsonism
Parkinson's disease (PD) is an idiopathic disorder that is the second most common cause of neurodegeneration, afflicting more than 1 million Americans over the age of 50. The scholarly documentation of PD's clinical hallmarks (bradykinesia, postural instability, rigidity, and tremor) by the physician James Parkinson in 1817 brought PD to medical attention. In addition to physical impairments, affected individuals also have a high rate of depression and an increased risk of death.
The first breakthrough in PD research came in the late 1950s through the contributions of Arvid Carlsson and coworkers. This group demonstrated that dopamine was present in the mammalian brain and proposed that it might be acting as a neurotransmitter (Carlsson et al., 1958) . They also showed that rabbits given reserpine, a dopaminedepleting agent, experienced rigidity that could be reversed through the administration of L-DOPA, the immediate precursor to dopamine. These advances led astute clinical pathologists to discover that dopamine was depleted in the substantia nigra pars compacta (SNpc) of postmortem brain tissue from patients with PD, and led clinicians to the first trial of L-DOPA in PD patients. For clinical neurology, this is perhaps the single best example of how basic research inspired drug treatment of a disorder. Forty-five years later, L-DOPA remains a mainstay of PD treatment.
The correlation of dopaminergic cell loss in the SNpc with the symptoms of PD allowed symptomatic relief, but did not identify the pathogenic mechanisms that cause the disease. The first step toward understanding these mechanisms came from a chance clinical observation by practicing neurologists (Langston et al., 1983) . They reported that a small group of intravenous drug users in California developed an acute but permanent Parkinsonian syndrome after using a meperidine analog tainted with the synthetic byproduct MPTP. Investigations in animal models revealed that MPTP is toxic to nigral dopaminergic neurons because its reactive metabolite, MPP+, is selective for the dopamine transporter and inhibits mitochondrial complex I. Animal models also revealed that other complex I inhibitors, such as the pesticides paraquat and rotenone, recapitulated not only the symptoms of Parkinsonism but also selective neurodegeneration of the SNpc and the development of cellular inclusions containing ubiquitin and α-synuclein that mimic Lewy bodies (the pathological hallmarks of PD). This information prompted clinicians to evaluate postmortem PD brain tissue for evidence of oxidative damage (which they found), and to discover that patients with sporadic PD have impaired complex I activity in peripheral tissues, suggesting a more widespread defect in oxidative mitochondrial function. These data support the conclusion that mitochondrial dysfunction contributes to the pathogenesis of PD, and
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Although the majority of PD cases occur sporadically, PD also runs in families. Ascertainment of such families by dedicated clinical neurologists has provided the key resource for the identification of genes that cause PD (α-synuclein, DJ-1, lRRK2, paRKin, and pinK1) and the identification of other loci whose relationship to PD is less clear. Although mutations in these genes are associated with less than 5% of the total number of PD cases, the linkage of α-synuclein and lRRK2 to sporadic disease reinforces the idea that understanding familial PD will inform us about the sporadic form of the disease.
Animal models harboring engineered mutations in the PD-associated genes α-synuclein and parkin have yielded valuable insights into the pathogenic mechanism of PD (Moore et al., 2005) . Overexpression of normal α-synuclein in fruit flies leads to selective degeneration of dopaminergic neurons (Feany and Bender, 2000) , a finding consistent with the discovery that duplications and triplications of the α-synuclein locus in human PD pedigrees cause PD (Singleton et al., 2003) . Recent observations from the fly model show that phosphorylation of wild-type α-synuclein decreases the solubility of the protein and promotes inclusion body formation (Chen and Feany, 2005) . Two human mutations in α-synuclein (A53T and A30P) cause increased aberrant phosphorylation of the protein and decreased inclusion body formation. These data suggest that protein aggregate formation may be a protective response of the cell that is sensitive to phosphorylation state. Mice lacking α-synuclein are protected from MPTP-mediated SNpc degeneration, suggesting that α-synuclein may mediate mitochondrial dysfunction (Dauer et al., 2002) . Finally, mice lacking both α-and β-synuclein demonstrate no obvious deleterious effects, suggesting that pharmacological strategies that decrease expression of α-synuclein might be both beneficial and well tolerated in humans (Chandra et al., 2004) .
Parkin acts as an E3 ubiquitin protein ligase, transferring ubiquitin residues to proteins and targeting them for destruction. Elevated levels of parkin protect neurons from the toxicity of α-synuclein and rescue the pinK1-deficient phenotype in fruit flies, suggesting that these PD-associated proteins function in a common pathway. Furthermore, mutation of parkin in Drosophila leads to mitochondrial swelling and subsequent apoptosis of muscle cells. These findings place parkin in a pathogenic pathway that involves mitochondrial dysfunction, which may be a key event in the sporadic form of PD.
Many questions remain to be answered. How do environmental factors affect the products of genes associated with PD? What is the underlying cause of Parkinsonism in people without known gene mutations? And, most importantly, how do we modify or stop the relentless progression of PD? The path has been charted for researchers to tackle these questions, providing hope that new treatments will be developed for this devastating disease.
Holoprosencephaly, Cancer and the SHH Signaling Pathway Holoprosencephaly (HPE) is the most common major malformation of human cerebral development, occurring in 1 in 8300 live births and up to 1 in 250 pregnancies. The disorder results from the failure of the developing forebrain to form paired cerebral hemispheres; other midline central nervous system (CNS) structures such as the basal ganglia, hypothalamus, pituitary, and thalamus can also be involved. The clinical reality is that HPE rarely occurs as an isolated entity. Roughly 80% of cases are associated with varying degrees of facial malformations ranging from mild (the presence of a single upper central incisor) to severe (cyclopia with a proboscis). HPE can also be part of larger genetic syndromes with more varied associated phenotypes.
Although the majority of HPE cases are sporadic, several clues point to a strong genetic contribution to the disorder. Chromosomal abnormalities account for up to 50% of live birth HPE cases, particularly when extracephalic findings are present. Other cases come from pedigrees with affected twins or family members from multiple generations with normal chromosomes. Careful phenotypic cataloging of multiple families by many clinicians led to the identification of 12 loci associated with HPE.
The first breakthrough in uncovering the gene defects responsible for HPE came with the discovery that disruption of the mouse sonic hedgehog (shh) gene resulted in an HPE phenotype complete with midline facial defects including cyclopia (Chiang et al., 1996) . Armed with this knowledge, Maximillian Muenke's group demonstrated that mutations in sHH were present in several families with HPE . But why would this gene cause HPE, and how would its identification shed light on the developmental mechanisms responsible for the disorder? Over fifteen years of work characterizing Drosophila development could now be brought to bear on a clinical problem. In Drosophila, Hedgehog (Hh) codes for a secreted protein that directs segmentation and the development of multiple fly organ systems, and its signaling pathway has been well characterized (see Figure 1 ). Mammalian homologs of Hh (such as shh) and other pathway components play important roles in mammalian development. The observation that shh is expressed in the developing vertebrate notochord and ventral neural tube led to the discovery of its importance in patterning of the CNS midline and, ultimately, to its link to HPE in shh-deficient mice. Evaluation of human mutations in other pathway proteins led to the identification of pTcH1 (one of two mammalian ptc homologs) as the gene associated with HPE7 (Ming et al., 2002) and Gli2, one of three mammalian cubitus interruptus homologs, as the gene associ-ated with the syndrome of pituitary anomalies with holoprosencephaly-like features (Roessler et al., 2003) . These are elegant examples of how the basic understanding of a developmental pathway can have unexpected relevance to a clinical disease.
Further insights into the pathogenesis of HPE came from synergy between basic and clinical research involving the rare Smith-Lemli-Opitz syndrome (SLOS) (Smith et al., 1964) . SLOS is an autosomal recessive disease characterized by mental retardation, polydactyly, genital malformations, cleft lip/palate, and poor growth. It is caused by mutations in the gene encoding 3β-hydroxysterol-∆7-reductase that result in up to a 2000-fold increase in levels of 7-dehydrocholesterol, the immediate precursor of cholesterol (see Figure 1 ). This information set the stage for the discovery of an unexpected link between the pathogenesis of SLOS and HPE. Philip Beachy's lab demonstrated that Hh proteins require a cholesterol adduct for proper extracellular localization and function (Porter et al., 1996) . In addition, teratogens that cause HPE, such as cyclopamine and jervine, disrupt transduction of the Hh signal in target tissues. These findings prompted an unbiased screening of HPE patients for abnormalities of cholesterol metabolism, uncovering a small number that also had undiagnosed SLOS (Kelley et al., 1996) . The careful clinical evaluation of a rare disease combined with a fundamental understanding of a basic biochemical pathway led to an expansion of a clinical spectrum, illustrating how information can go from the clinic to the bench and back again.
In addition to its detrimental effects on normal morphogenesis, dysregulation of the SHH signaling pathway can lead to the development of medulloblastoma, the most common malignant brain tumor of childhood (see Figure 1) . Medulloblastomas typically arise in the cerebellum, most likely from the external granular layer, a secondary proliferative neuroepithelium where cell division and maturation are regulated by SHH. Dysregulated activity of the pathway through inactivation of PTCH (or SUFU) or activation of GLI can lead to malignant transformation of external granule layer cells. Mutations in these genes, along with activating mutations in smoothened (SMO), are also associated with other cancers such as basal cell carcinoma and rhabdomyosarcoma.
The mainstays of treatment for medulloblastoma are chemotherapy, radiation therapy, and surgery, all of which have long-term adverse effects on growth and development. By using specific inhibitors of the SHH pathway, two groups were able to change the growth dynamics of malignant cells in vitro and to treat medulloblastomas in living animals (Berman et al., 2002; Romer et al., 2004) . In addition to being an effective therapeutic strategy, SHH pathway inhibitors like cyclopamine selectively target malignant cells and have little effect on normal tissues, potentially offering a therapeutic avenue that can minimize toxicity without compromising effectiveness of treatment.
Putting a Tone Back in Deaf Ears with Atoh1
Identification of the molecule, Atonal, that drives internal mechanoreceptor (proprioceptor) development in Drosophila has provided remarkable insights into hearing loss in humans. Mechanoreception is the detection of tension, pressure, and displacement. The canonical mechanoreceptor in vertebrates and invertebrates consists of a specialized, ciliated cell that can detect movement and vibration (see Figure 2 ). Modifications to this basic scheme allow organisms to detect movement against their body surface, hear sounds, and determine their position in space. In Drosophila, the chordotonal organs (CHOs) act as proprioceptors in the fly cuticle; Johnston's organ, an array of CHOs found in the second antennal segment, is important in hearing and detects the fly's position with respect to gravity. CHOs are composed of a single neuron surrounded by multiple support cells (see Figure 2) . The sensory neuron is specified by expression of the atonal gene, which encodes a basic helix-loop-helix transcription factor that is both necessary and sufficient for CHO specification. Sonic hedgehog (SHH) binds to its receptor patched (PTCH), releasing inhibition of smoothened (SMO). Cholesterol modification (blue circle) of SHH is necessary for the proper localization and signaling of SHH. Activated SMO inhibits suppressor of fused (SUFU), which releases inhibition of gliomas-associated oncogene homolog (GLI). GLI is a transcription factor that drives SHH-induced gene expression. Holoprosencephaly (HPE)-related conditions resulting from mutations in pathway components are pink; cancers caused by pathway mutations are purple. 7-DHCR, 3β-hydroxysterol-∆7-reductase; BCNS, basal cell nevus syndrome; PAHPL, pituitary anomalies with holoprosencephaly-like features; SLOS, Smith-Lemli-Opitz Syndrome.
The importance of atonal in the development of the proprioceptive system in the fruit fly prompted a search for homologous genes in the mouse, leading to the identification of five genes with varying expression patterns. atoh1 (Math1) is expressed throughout the embryonic dorsal neural tube, which gives rise to the central sensory system, from the rostral hindbrain to the caudal spinal cord. This expression pattern, coupled with the uncoordinated phenotype of viable atonal-deficient flies, led our lab to engineer atoh1-deficient mice to determine whether the gene played a role in the development of the mammalian proprioceptive system.
Like atonal-deficient flies, atoh1-deficient mice have disrupted proprioceptive and auditory systems. Multiple components of the central spinocerebellar system (granule and deep nuclear neurons of the cerebellum, multiple brainstem nuclei, and dorsal commissural neurons of the spinal cord), which coordinates movement and motor learning by integrating proprioceptive and vestibular inputs, express atoh1 and are missing in atoh1-deficient mice (see Figure 2) (Wang et al., 2005) . In the mouse, Merkel cells of the skin mediate pressure and touch sensation and express atoh1, although the effects of deleting this gene on this cell population are not clear. In the auditory system, neurons in the cochlear nuclei and hair cells of the inner ear are absent in atoh1-deficient mice.
This last observation has particular relevance for clinical medicine, as hearing loss is a common and devastating form of sensory impairment. Roughly 10% of the general population (about 21 million people in the United States alone) has hearing loss great enough to impair communication; this proportion increases to 50% by age 80. Notably, about 80% of sensorineural hearing loss cases in adults occur secondary to loss of sensory hair cells in the inner ear. If, as in flies, atoh1 is sufficient to direct the specification of hair cell precursors, it might be possible to repopulate deaf ears with a new complement of hair cells and thereby restore hearing.
To test this hypothesis, normal cochlea and utricles from the inner ear of early postnatal rats were grown in tissue culture and transfected with atoh1, resulting in the conversion of sensory epithelial cells into extra hair cells in the absence of cell division (Zheng and Gao, 2000) . The human atoh1 homolog, Hath1, produced similar results, and utricles depleted of hair cells by ototoxic drug application also responded to atoh1 treatment. Most importantly, a recent study demonstrated an improvement in auditory brainstem evoked responses to sound in guinea pigs treated by injecting adenovirus expressing atoh1 into their cochlea (Izumikawa et al., 2005) . This represents the first evidence of functional recovery in a mammal after the onset of deafness.
Although challenges remain regarding gene therapy delivery systems in the primate and the potential need for concomitant regeneration of auditory nerve fibers in addition to hair cells, this is an exciting development that holds great promise for the future. As the functions of developmentally important genes are characterized, one hopes that regeneration of other sensory systems such as vision and touch will also become a viable reality in the future. 
Conclusion
Although resources are limited, it is essential that we maintain healthy funding for basic science as part of our national approach to treating human disease. In the course of their studies, basic scientists need to actively seek connections to human conditions to ensure that the relevance of their research is not overlooked. To help direct this endeavor, we must recognize the value of crosstalk with the clinical world and involve clinicians so that basic science advances can be put into a meaningful clinical framework. This means that the clinical environment must be receptive and must enable physicians to take the time to recognize and report unusual clinical observations and to ponder discoveries from the basic research world. Without these key ingredients, we will be hard-pressed to meet the challenges presented by human disease. It is only by the continued marriage of bench research and medicine and open communication between the two disciplines that we can hope to uncover ways to halt the progression or reverse the effects of neurological disorders.
